Treating pulmonary embolism: How safe and effective are new devices?

October 04, 2019

PHILADELPHIA -- Pulmonary embolism (PE), a blood clot lodged in one of the pulmonary arteries in the lungs, is the third leading cause of cardiovascular-related death in the United States. While most patients are treated with anticoagulants (commonly known as blood thinners), the use of novel interventional devices that remove or dissolve clots in the lungs has significantly increased in recent years. Yet, there is little data--particularly, as it pertains to the treatment of patients with "intermediate-risk PE"--that suggests these approaches are more safe and effective than the use of anticoagulation alone, according to a new scientific statement from the American Heart Association (AHA) that was led by Penn Medicine.

The statement will be published today in Circulation and simultaneously presented by Jay S. Giri, MD, MPH, an assistant professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania, at the 5th Annual Pulmonary Embolism Symposium in Boston.

"While the emergence of these interventional devices offers a new approach to treat pulmonary embolism, questions exist about when they should be administered and which patients would benefit the most. This statement aims to help stratify the risks associated with these approaches and guide clinical practice," said Giri, who chaired the multi-disciplinary committee, comprised of 12 experts from nine different institutions, that published the research.

Pulmonary embolism, which is most often caused by blood clots that travel to the lungs from deep veins in the legs, affects as many as 900,000 people each year in the United States. Historically, the majority of patients with PE have been treated with blood thinners, which help to prevent new clots from forming but do not eliminate existing clots. However, adverse outcomes in patients with intermediate and high-risk PE--despite the use of anticoagulants--prompted the development of novel therapeutic approaches, including catheter-directed thrombolysis (dispensing "clot-busting" medication via a catheter that is threaded through the groin) and catheter-based embolectomy (removing the clot through a minimally invasive procedure). As of now, the U.S. Food and Drug Administration (FDA) has cleared two devices for the interventional treatment of PE, though many others are in the development pipeline.

Despite the clearances, there is limited evidence supporting the safety of the interventional therapies against more conservative approaches, partly because of the FDA's decision to designate these devices as Class II (moderate risk), authors say. According to the FDA, Class II devices include wheelchairs and some pregnancy tests, while Class III (high risk) devices--those that present a potential unreasonable risk of illness or injury--include recently evaluated cardiovascular devices, such as transcatheter heart valves and drug-coated balloons for peripheral artery disease. Unlike Class III devices, which require premarket approval from the FDA--the highest form of device regulation--prior to device sales and marketing, Class II devices can receive clearance via the 510(k) clearance pathway. As a result, authors argue that high-level evidence demonstrating the safety and effectiveness of the devices, and justifying their use, will not be available before widespread marketing.

In this statement, researchers sought to raise awareness of the novel treatment approaches, advise of the potential benefits and risks of endovascular PE intervention and outline appropriate uses, including identifying which patients would derive the greatest benefit. While decisions to use interventional therapy are primarily driven by the severity of a patient's condition and their risk of dying, authors note that it should also be influenced by patient-specific risk factors for comorbidities and bleeding. Finally, the team sought to lay out principles for research in the field, including appropriate study designs and patient criteria for needed future clinical trials.

The team concluded that patients who are at the highest risk of dying of PE and lowest risk for bleeding benefit the most from more invasive therapies. Patients considered low-risk should be treated with anticoagulants alone. The team discouraged routine administration of interventional therapies to patients at intermediate risk, with patients in this group necessitating the most careful personalized assessment of risks and benefits of therapy.

"Given the minimal short-term risk and low cost associated with anticoagulation alone, these interventional therapy devices must prove safety and effectiveness compared to anticoagulants in randomized clinical trials," Giri said. "As we move forward, it's critical to design randomized trials that enable us to measure clinically meaningful differences in patient outcomes and quality of life."
Additional Penn Medicine authors include Nimesh D. Desai, MD, PhD, and Taisei Kobayashi, MD.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.

University of Pennsylvania School of Medicine

Related Pulmonary Embolism Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

High risk of deep vein thrombosis and pulmonary embolism in patients with COVID-19
In a systematic review of the worldwide published data on ''Venous thromboembolism (VTE) in COVID-19 patients'', researchers from the Department of Medicine I (MedUni Vienna), provide an in-depth analysis on the risk of VTE in patients hospitalised for COVID-19.

Trial clarifies which patients with acute pulmonary embolism can be managed at home
Patients with acute pulmonary embolism can be selected for home management using the sPESI score or the Hestia criteria, according to results of the HOME-PE trial presented in a Hot Line session today at ESC Congress 2020.1 Principal investigator Professor Pierre-Marie Roy of the University Hospital of Angers, France said: ''The pragmatic Hestia method was at least as safe as the sPESI score for triaging haemodynamically stable pulmonary embolism patients for outpatient care.''

Barriers exist to using risk stratification tools to evaluate pulmonary embolism in the ED
Common barriers exist to the use of risk stratification tools in the evaluation of pulmonary embolism in the emergency department and provide insight into where to focus efforts for future implementation endeavors.

Pulmonary embolism and COVID-19
Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Better way to interpret blood tests to diagnose pulmonary embolism
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.

Reversed halo signs manifest in septic pulmonary embolism due to IV drug use
According to an article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology (AJR), reversed halo signs were frequently observed on the chest CT scans of patients with IV substance use disorder-related septic pulmonary embolism.

Treating pulmonary embolism: How safe and effective are new devices?
A new scientific statement from the American Heart Association identifies the risks and benefits of novel interventional devices compared to anticoagulation alone in the treatment of patients with pulmonary embolism.

Read More: Pulmonary Embolism News and Pulmonary Embolism Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to